RayzeBio
United States · $258.0M raised
- Business Model
- B2B
- Website
- rayzebio.com
- Total Funding
- $258.0M
- Last Round
- $108.0M Series CSep 2022
- Rounds
- 3
About
Radiopharmaceutical company developing drug conjugates for the treatment of cancer.
Summary
RayzeBio is a Biotech company based in United States. It has raised $258.0M in total across 3 rounds, most recently a $108.0M Series C round in Sep 2022. Investors include venBIO Partners, Jerel Davis and Venrock.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Sep 2022
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...